Organon & Co. Shares Drop 6.4% as Analysts Forecast Weak Growth

Got story updates? Submit your updates here. ›

Organon & Co. (NYSE:OGN), a global healthcare company focused on women's health, biosimilars, and established brands, saw its stock price fall 6.4% during trading on Monday. Several research firms have recently downgraded the company's stock, with Wall Street Zen moving it from 'buy' to 'hold' and Zacks Research changing its rating to 'strong sell'. The stock is currently trading at $8.26, down from its previous close of $8.83.

Why it matters

Organon & Co.'s stock performance and the negative analyst sentiment surrounding the company could signal broader challenges in the pharmaceutical industry, particularly in the women's health and biosimilar segments. Investors will be closely watching the company's financial results and strategic direction as it navigates these market conditions.

The details

The drop in Organon & Co.'s stock price comes amid a 25% increase in trading volume compared to the average session. Wall Street analysts have cited concerns over the company's financial performance, with one firm downgrading the stock to a 'strong sell' rating and another moving it to a 'hold' recommendation. The company's debt-to-equity ratio of 11.47 and its recent earnings miss of $0.10 per share compared to the expected $0.73 per share have also contributed to the negative sentiment.

• Organon & Co.'s stock price fell 6.4% during trading on Monday, April 13, 2026.
• The company's 50-day simple moving average is $6.93, and its 200-day simple moving average is $7.73.

What’s next

Investors will be closely monitoring Organon & Co.'s upcoming financial results and any strategic changes the company makes in response to the negative analyst sentiment and stock performance.